Impact of season and geography on COPDCompEx: a composite endpoint for COPD trials - 05/08/26
Highlights |
• | COPDCompEx aims to address the limitations of exacerbations as a study endpoint. |
• | COPDCompEx is a viable rate endpoint when time or recruitment are limiting factors. |
• | A higher annualised event rate was seen with COPDCompEx versus exacerbations. |
• | Less variation in season/geography-related treatment effect seen with COPDCompEx. |
Abstract |
Background |
Exacerbations are a common outcome measure in chronic obstructive pulmonary disease (COPD)-related studies, despite limitations. COPDCompEx, a composite endpoint that includes moderate and severe exacerbations, acute worsening events and early treatment discontinuations, was developed to address these limitations. This post hoc analysis evaluated COPDCompEx as a rate endpoint.
Methods |
Data from seven randomised controlled trials (three development, four test) were used to refine the COPDCompEx rate endpoint. Acute worsening events, moderate exacerbations, severe exacerbations and early treatment discontinuations were considered COPDCompEx events. Acute worsening events were algorithmic combinations of deteriorations in peak expiratory flow, reliever use and symptoms. Aspects of COPDCompEx, used as a rate endpoint, were tested with combinations of model (negative binomial, Andersen–Gill, Cox proportional hazard frailty survival) and inter-event gaps (7, 10 or 14 days). Estimated minimum sample size, treatment effect ratios and annualised event rate were compared between COPDCompEx and exacerbations.
Results |
COPDCompEx, with a negative binomial model and 14-day inter-event gap, proved optimal based on treatment effect ratios (exacerbations) and estimated minimum sample size. COPDCompEx had an annualised event rate 3.0-times higher in development trials, and 4.5-times higher in test trials, compared with exacerbations. Season- or geography-related treatment effect variations were generally smaller than or comparable to those seen with exacerbations.
Conclusions |
COPDCompEx is a viable rate endpoint for clinical trials where time or recruitment are limiting factors. This endpoint generates significantly more events than exacerbations alone and may, therefore, reduce variation in treatment efficacy resulting from seasonal/geographical variation.
Trial registration |
NCT00206154, NCT00206167, NCT00419744, NCT00363896, NCT00358436, NCT01854645, NCT01854658
Le texte complet de cet article est disponible en PDF.Keywords : COPD, COPD exacerbations, Outcome measures
Abbreviations : AER, AWE, BD, CI, COPD, FEV 1 , FVC, HCRU, HR, HRQoL, PEF, RR
Plan
Vol 90
Article 101305- novembre 2026 Retour au numéro
Article précédent
- Exploring the discrepancies in restrictive ventilatory defect classifications: Associations with dyspnea and insights from ATS 1991, ATS/ERS 2005, and ATS/ERS 2022 Systems
- Khouloud Kchaou, Yosra Abdelhedi, Chaima Briki, Soumaya Khaldi, Saloua Ben Khamsa Jameleddine
- Efficacy and safety of balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension associated with sickle cell disease
- Mitja Jevnikar, Sarah Macisaac, Philippe Brenot, François Lionnet, Aline Santin, Anne Roche, Christelle Chantalat-Auger, Yoichi Sugiyama, Thomas d'Humières, Athénaïs Boucly, Olivier Sitbon, David Montani, Olaf Mercier, Samuel Dolidon, Jean-Noel Andarelli, Pablo Bartolucci, Elie Fadel, Marc Humbert, Xavier Jais, Laurent Savale
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?